Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,148,600.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00.
• On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00.
• On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $79.77, for a total value of $153,397.71.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock traded up $0.20 during midday trading on Friday, reaching $107.20. The company’s stock had a trading volume of 861,533 shares, compared to its average volume of 1,560,954. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $111.15. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The business has a 50-day moving average price of $93.73 and a 200-day moving average price of $76.97. The stock has a market cap of $12.17 billion, a PE ratio of 32.00, a price-to-earnings-growth ratio of 0.41 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business’s quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on HALO. HC Wainwright reissued a “buy” rating and issued a $115.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, September 2nd. UBS Group reiterated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Wells Fargo & Company raised their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Finally, Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in HALO. Measured Wealth Private Client Group LLC grew its stake in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares during the last quarter. Larson Financial Group LLC raised its position in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the last quarter. MidFirst Bank acquired a new position in Halozyme Therapeutics during the 2nd quarter worth about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $28,000. Finally, Quantbot Technologies LP bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $30,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.